FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.
What happened
FDA reviewed Levity's website in December 2025 and found it offered compounded semaglutide and liraglutide products. The site showed labels with “Levity” on them, suggesting Levity was the compounder even though FDA says it is not, and it used claims comparing the products to Ozempic, Wegovy, and Saxenda. FDA said those claims were false or misleading and made the products misbranded.
What FDA found
Website labels pictured with “Levity” imply Levity compounded the drugs, but FDA says it did not.
FDCA § 502(a) [21 U.S.C. § 352(a)]; FDCA § 502(bb) [21 U.S.C. § 352(bb)]; 21 CFR § 201.1(h)(2)The website claim “The same ingredient as Ozempic® + Wegovy®” falsely implies FDA approval or evaluation.
FDCA § 502(a) [21 U.S.C. § 352(a)]; FDCA § 502(bb) [21 U.S.C. § 352(bb)]The website claim “The power of Saxenda®” falsely implies FDA approval or evaluation.
FDCA § 502(a) [21 U.S.C. § 352(a)]; FDCA § 502(bb) [21 U.S.C. § 352(bb)]Selling or shipping these misbranded drugs in interstate commerce is prohibited.
FDCA § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Levity to respond within 15 working days describing steps to correct the violations, including identifying who makes the compounded products, providing sample labeling, and fixing or removing the misleading website claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounders whose products are advertised by telehealth sites
- marketing teams writing drug claims for compounded products
This is a summary. Read the original letter on fda.gov.